Advertisement

European Journal of Clinical Pharmacology

, Volume 75, Issue 3, pp 351–361 | Cite as

Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation

  • Yushi Kashihara
  • Yui Terao
  • Kensaku Yoda
  • Takeshi Hirota
  • Toshio Kubota
  • Miyuki Kimura
  • Shunji Matsuki
  • Masaaki Hirakawa
  • Shin Irie
  • Ichiro IeiriEmail author
Pharmacokinetics and Disposition
  • 232 Downloads

Abstract

Background

Magnesium oxide (MgO) is often co-prescribed with L-dopa/carbidopa (LDCD) to improve constipation in Parkinson’s disease patients. The mixing of L-dopa and MgO has been shown to degrade L-dopa; however, there is no interaction study on humans. We proposed mechanisms for the interaction between LDCD and MgO and conducted pharmacokinetic studies on rats and humans. To assess pharmacodynamic changes with the MgO treatment, we applied a model-based meta-analysis (MBMA).

Methods

The effects of MgO on the stabilities of L-dopa and carbidopa were evaluated in in vitro studies. We conducted pharmacokinetic interaction studies of MgO and LDCD on rats and healthy volunteers. A clinical study was conducted with an open-label, non-randomized, single-arm, and two-phase study. In MBMA, we constructed a population pharmacokinetic/pharmacodynamic model of L-dopa and predicted the effects of the MgO treatment on the pharmacodynamics of L-dopa.

Results

In vitro results suggested that carbidopa was unstable under alkaline pH conditions. Reductions in plasma LDCD concentrations were observed after oral-MgO/oral-LDCD, but not in oral-MgO/i.v.-LDCD treatments in rats, suggesting that the gastrointestinal tract is an interaction site. A healthy volunteer study showed that MgO was also associated with significant decreases of 35.3 and 80.9% in the AUC0–12 of L-dopa and carbidopa, respectively. A model-based simulation suggested that the MgO treatment was undesirable for the effectiveness of L-dopa.

Conclusions

This is the first study to show a clear pharmacokinetic interaction between LDCD and MgO in humans. Further investigations to confirm the effects of MgO on the pharmacodynamics of L-dopa are required.

Keywords

L-Dopa/carbidopa Magnesium oxide Interaction Pharmacokinetics Model-based meta-analysis 

Notes

Acknowledgments

The authors are grateful to the subjects who were involved in this study and the staff at the SOUSEIKAI Fukuoka Mirai Hospital Clinical Research Center. The authors thank Satoru Koyanagi and Naoya Matsunaga for animal handling assistance.

Author contributions

Y.K., Y.T., and T.H. wrote the paper. Y.K., Y.T., T.K., M.K., M.H., S.I., T.H., and I.I designed the research. Y.K., Y.T., and K.Y performed the research. Y.K. and Y.T. analyzed the data. I critically reviewed the manuscript for intellectual content.

Funding

This study was funded by the Japan Research Foundation for Clinical Pharmacology.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All procedures performed in studies involving animals were in accordance with the Experimental Animal Care and Use Committee of Kyushu University according to the National Institutes of Health guidelines.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

228_2018_2568_MOESM1_ESM.docx (336 kb)
ESM 1 (DOCX 336 kb)

References

  1. 1.
    de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5:525–535CrossRefGoogle Scholar
  2. 2.
    Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79:368–376CrossRefGoogle Scholar
  3. 3.
    Nutt JG, Fellman JH (1984) Pharmacokinetics of levodopa. Clin Neuropharmacol 7:35–49CrossRefGoogle Scholar
  4. 4.
    Abrams WB, Coutinho CB, Leon AS, Spiegel HE (1971) Absorption and metabolism of levodopa. JAMA 218:1912–1914CrossRefGoogle Scholar
  5. 5.
    Marsden CD, Barry PE, Parkes JD, Zilkha KJ (1973) Treatment of Parkinson’s disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase. J Neurol Neurosurg Psychiatry 36:10–14CrossRefGoogle Scholar
  6. 6.
    Borri-Voltattorni C, Minelli A, Borri P (1977) Interaction of L-alpha-methyl-alpha-hydrazino-3,4 dihydroxyphenylpropionic acid with dopa-decarboxylase from pig kidney. FEBS Lett 75:277–280CrossRefGoogle Scholar
  7. 7.
    Porter CC, Watson LS, Titus DC, Totaro JA, Byer SS (1962) Inhibition of dopa decarboxylase by the hydrazino analog of α-methyldopa. Biochem Pharmacol 11:1067–1077CrossRefGoogle Scholar
  8. 8.
    Marsden CD, Parkes JD, Rees JE (1973) A year’s comparison of treatment of patients with Parkinson’s disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet 2:1459–1462CrossRefGoogle Scholar
  9. 9.
    Bartholini G, Burkard WP, Pletscher A (1967) Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature 215:852–853CrossRefGoogle Scholar
  10. 10.
    Nussbaum RL, Ellis CE (2003) Alzheimer’s disease and Parkinson’s disease. N Engl J Med 348:1356–1364CrossRefGoogle Scholar
  11. 11.
    Dinning PG, Di Lorenzo C (2011) Colonic dysmotility in constipation. Best Pract Res Clin Gastroenterol 25:89–101CrossRefGoogle Scholar
  12. 12.
    Omotani H, Yasuda M, Ishii R, Ikarashi T (2016) Analysis of L-dopa-derived melanin and a novel degradation product formed under alkaline conditions. J Pharm Biomed Anal 125:22–26CrossRefGoogle Scholar
  13. 13.
    Siddhuraju P, Becker K (2001) Rapid reversed-phase high performance liquid chromatographic method for the quantification of L-dopa tetrahydroisoquinoline compounds from Mucuna beans. Food Chem 72:389–394CrossRefGoogle Scholar
  14. 14.
    Mds T, Goetz CG, Poewe W, Rascol O, Christina S (2003) State of the art review. The unified Parkinson’s disease rating scale (UPDRS): status and recommendations. Society 18:738–750Google Scholar
  15. 15.
    Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25:358–371CrossRefGoogle Scholar
  16. 16.
    Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS 13:143–151CrossRefGoogle Scholar
  17. 17.
    Nguyen TH, Mouksassi MS, Holford N et al (2017) Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacometrics Syst Pharmacol 6(2):87–109CrossRefGoogle Scholar
  18. 18.
    Adamiak U, Kaldonska M, Klodowska-Duda G, Wyska E, Safranow K, Bialecka M, Gawronska-Szklarz B (2010) Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Clin Neuropharmacol 33:135–141CrossRefGoogle Scholar
  19. 19.
    Devos D, Lejeune S, Cormier-Dequaire F, Tahiri K, Charbonnier-Beaupel F, Rouaix N, Duhamel A, Sablonnière B, Bonnet AM, Bonnet C, Zahr N, Costentin J, Vidailhet M, Corvol JC (2014) Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson’s disease. Park Relat Disord 20:170–175CrossRefGoogle Scholar
  20. 20.
    Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H (1997) Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with Parkinson’s disease. Mov Disord 12:497–505CrossRefGoogle Scholar
  21. 21.
    Yamamoto M, Yokochi M, Kuno S, Hattori Y, Tsukamoto Y, Narabayashi H, Tohgi H, Mizuno Y, Kowa H, Yanagisawa N, Kanazawa I (1997) Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson’s disease. J Neural Transm 104:229–236CrossRefGoogle Scholar
  22. 22.
    Ruottinen HM, Rinne UK (1996) Effect of one month’s treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 19:222–233CrossRefGoogle Scholar
  23. 23.
    Ruottinen HM, Rinne UK (1996) Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 60:36–40CrossRefGoogle Scholar
  24. 24.
    Sun W, Klamerus KJ, Yuhas LM et al (2017) Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food intake conditions. Clin Pharmacol Drug Dev 6:14–626CrossRefGoogle Scholar
  25. 25.
    Lau YY, Gu W, Lin T, Viraswami-Appanna K, Cai C, Scott JW, Shi M (2017) Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol 79:1119–1128CrossRefGoogle Scholar
  26. 26.
    Heikkinen H, Varhe A, Laine T, Puttonen J, Kela M, Kaakkola S, Reinikainen K (2002) Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose. Br J Clin Pharmacol 54:363–371CrossRefGoogle Scholar
  27. 27.
    Jorga K, Fotteler B, Sedek G, Nielsen T, Aitken J (1998) The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J Neurol 245:223–230CrossRefGoogle Scholar
  28. 28.
    Iwaki H, Nishikawa N, Nagai M, Tsujii T, Yabe H, Kubo M, Ieiri I, Nomoto M (2015) Pharmacokinetics of levodopa/benserazide versus levodopa/carbidopa in healthy subjects and patients with Parkinson’s disease. Neurol Clin Neurosci 3:68–73CrossRefGoogle Scholar
  29. 29.
    Maekawa H, Takagishi Y, Doi Y, Ohsumi K, Otomune T (1971) Yakuzaiaku 31:266–272Google Scholar
  30. 30.
    Nutt JG, Woodward WR, Anderson JL (1985) The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol 18:537–543CrossRefGoogle Scholar
  31. 31.
    Kaakkola S, Männistö PT, Nissinen E, Vuorela A, Mäntylä R (1985) The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa. Acta Neurol Scand 72:385–391CrossRefGoogle Scholar
  32. 32.
    Rajan KS, Manian AA, Davis JM, Dekirmenjian H (1976) Metal chelates of L-DOPA for improved replenishment of dopaminergic pools. Brain Res 107(2):317–331CrossRefGoogle Scholar
  33. 33.
    Lin MS, Sun P, Yu HY (1998) Evaluation of buffering capacity and acid neutralizing-pH time profile of antacids. J Formos Med Assoc 97:704–710Google Scholar
  34. 34.
    Jorga K, Banken L, Fotteler B, Snell P, Steimer JL (2000) Population pharmacokinetics of levodopa in patients with Parkinson’s disease treated with tolcapone. Clin Pharmacol Ther 67:610–620CrossRefGoogle Scholar
  35. 35.
    Triggs EJ, Charles BG, Contin M, Martinelli P, Cortelli P, Riva R, Albani F, Baruzzi A (1996) Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients. Eur J Clin Pharmacol 51:59–67CrossRefGoogle Scholar
  36. 36.
    Simon N, Viallet F, Boulamery A, Eusebio A, Gayraud D, Azulay JP (2016) A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson’s disease patients. Eur J Clin Pharmacol 72:423–430CrossRefGoogle Scholar
  37. 37.
    Schrag A, Sampaio C, Counsell N, Poewe W (2006) Minimal clinically important change on the Unified Parkinson’s Disease Rating Scale. Mov Disord 21:1200–1207CrossRefGoogle Scholar
  38. 38.
    Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D, Olanow CW (2004) Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson’s disease patients. Mov Disord 19:916–923CrossRefGoogle Scholar
  39. 39.
    Parkinson Study Group (1997) Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. JAMA 278:125–130CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Yushi Kashihara
    • 1
  • Yui Terao
    • 1
  • Kensaku Yoda
    • 1
    • 2
  • Takeshi Hirota
    • 1
  • Toshio Kubota
    • 3
  • Miyuki Kimura
    • 4
  • Shunji Matsuki
    • 4
  • Masaaki Hirakawa
    • 2
  • Shin Irie
    • 4
  • Ichiro Ieiri
    • 1
    Email author
  1. 1.Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical SciencesKyushu UniversityHigashi-kuJapan
  2. 2.Hospital Pharmacy, Fukuoka Tokushukai Medical CenterFukuokaJapan
  3. 3.Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical SciencesKyushu UniversityFukuokaJapan
  4. 4.SOUSEIKAI Fukuoka Mirai Hospital Clinical Research CenterFukuokaJapan

Personalised recommendations